Prevalence of HIV/AIDS among Iranian Prisoners: A Review Article

Morteza Akbari MSc1, Maryam Akbari MSc2, Ahmad Naghibzadeh-Tahami MSc3, Hassan Joulaei PharmD, PhD1, Maryam Nasiriyan PhD4, Maryam Hesampour MSc5, Kamran Bagheri-Lankarani MD6

Abstract

Background: Worldwide, prisoners are more at risk of being infected by human immunodeficiency virus (HIV) as well as hepatitis C and B in comparison with other risk groups. The combination of acquired immune deficiency syndrome (AIDS), addiction and prison are factors that threaten the health of our society. Influence of risky behaviors is so common on transmission of AIDS into prisoners’ bodies. This study used available information and reports to investigate the prevalence of HIV in Iranian prisons.

Methods: The following review of documents available in national and foreign databases, a total of 26 studies were investigated and required information was extracted from both the full papers and abstracts.

Findings: The selected studies differed methodologically in their sampling method and data collection tools. Within the 26 studies analyzed, there was a combined study cohort of 39,707 people in whom HIV prevalence varied between 0% and 24.40%.

Conclusion: In this study, HIV prevalence ranged widely among the prisoners, and in most of these studies, the rate in Iran was higher than that of other countries. The prevalence of disease was highest among intravenous drug users. Unless proper preventive and control plans among risk groups such as prisoners are not implemented in a timely and suitable manner, the risk of infection in the broader society will increase.

Keywords: HIV; AIDS; Prisoners; Iran; Prevalence; Incidence

Citation: Akbari M, Akbari M, Naghibzadeh-Tahami A, Joulaei H, Nasiriyan M, Hesampour M, et al. Prevalence of HIV/AIDS among Iranian Prisoners: A Review Article. Addict Health 2016; 8(3): 195-206.

Received: 18.02.2016 Accepted: 21.04.2016

1- Shiraz HIV/AIDS Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2- PhD Student, Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3- PhD Student, Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
4- Assistant Professor, Department of Biostatistic and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
5- Department of Health Education and Promotion, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran
6- Professor, Health Policy Research Center AND Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence to: Kamran Bagheri-Lankarani, Email: lankaran@sums.ac.ir

Addict Health, Summer 2016; Vol 8, No 3

http://ahj.kmu.ac.ir, 5 July
Introduction

Prisoners worldwide are subject to infection by human immunodeficiency virus (HIV), hepatitis C and other diseases with those who use intravenous drugs at greater risk.\(^1,2\)

Acquired immune deficiency syndrome (AIDS), addiction, and prison are a combination of risk factors that threaten the health of society. These risk factors contribute to the spread of AIDS among prisoners.\(^1,3\) Not only are prisoners subject to HIV infection but they are also considered as a source for spreading the virus into society.\(^4\) The prevalence HIV in prisons varies in different countries with this being 0-2\% in Australia, 2\% in America, 11\% in Latin American countries, 10\% in the Middle East, and 20\% in African desert areas.\(^5,6\)

HIV infection prevalence in prisons is usually several times higher than its prevalence in society;\(^7,8\) for example, the rate is 4-6 times higher among American prisoners and 10 times higher in France compared to the common population,\(^9\) while this rate in Iranian prisons is 8 times that of the general population.\(^2\) In recent years, in the Middle East area and along the Eastern Mediterranean Sea, including Iran, the number of intravenous drug addicts with HIV has increased and recognized cases in Iran include those who spend time in prisons and re-education centers.\(^10\)

In 1990, a HIV epidemic was reported in some Iranian prisons and its main cause was insecure use of intravenous drugs in prisons. This resulted in planning and implementing plans for harm-reduction such as methadone maintenance treatment (MMT) and distributing disposable syringes among the prisons; this resulted in about 25400 prisoners participating in MMT programs by 2009.\(^11,12\)

The studies reviewed show that affliction by infections such as HIV, venereal diseases and hepatitis in prisons rises daily, and there is a universal need for an integrated plan to reduce the transfer risk of these diseases. Many believe prisons are appropriate places for preventive interventions from HIV infection.\(^13\) There have been diverse studies conducted in Iran assessing HIV prevalence among prisoners. Yet it seems this diversity and dispersal has resulted in a lack of planning. This study aimed to gather information from published reports to generate a broader view about HIV prevalence in Iranian prisons and to provide valuable information that can guide policy makers and planners in this area.

Methods

Searching guidelines

In the study, the first step involved gathering published national documents by searching the academic Jihad database, Magiran and Iran Medex database, using keywords of “HIV,” “AIDS,” and “prisoners” with related cases then extracted. All documents, articles, and abstracts related to the research subject were gathered searching PubMed, ISI web of knowledge, Scopus and Science Direct databases with keywords HIV and AIDS and prison along with operator “AND” and keywords, Prisoner and Iran and their full texts were obtained. In addition, we used resources from the documents and experts’ and professionals’ opinions in the field of HIV/AIDS to access related titles. After extracting the documents, information of articles, abstract of articles in congresses and reports of research plans were all entered into the software program Endnote and repeated cases were omitted. In the next step, unrelated studies were deleted by reviewing titles and then the relatedness of remaining studies were assured, and unrelated cases were omitted by referring to the summary of the articles and their full text (Figure 1).

Quality assessment and information extraction

Following this data entry process, a checklist comprising six questions was used to evaluate quality of information and extract it, there were two questions about the research object, one about the place of research, one about the method of sampling and the remaining two questions related to the method of gathering information. Quality of information was evaluated by investigating the full text of the documents with the studies allocated into three groups of high, medium, and low quality based on quality score. Next, information related to research subject, including the year the study was conducted; statistical population, sample volume, sampling method, HIV prevalence, and sexually transmitted infections (STIs) were obtained by referring to the full text of articles.

Results

From 370 papers addressing different stages of
research, 26 studies met the selection criteria with 11 published in national reliable research journals, 11 were published in international reliable journals, one was reported by the World Health Organization and three cases were reported by the Health Ministry of Iran. Although these studies were performed in different provinces and used different methods and statistical population and sometimes had different aims, in most cases the results were similar. Among the studies completed using prisoners who inject drugs the highest prevalence of HIV was reported by universal studies, Kheirandish et al., and Hosseini et al. with 24.40%; the lowest prevalence was related Azarkar and Sharifzadeh’s study with 0 (Table 1).

The STI prevalence among prisoners varied between 2.38% in Khamisipoor and Tahmasebi’s study and 28.60% in Rahbar et al.’s study (Table 2).

**Discussion**

This study is one of many that have investigated HIV/AIDS prevalence in Iranian prisons. Although these diseases have not yet reached epidemic levels among the public population and entered a stage of concentrated prevalence, they are increasing among at risk groups such as prisoners. In other parts of the world, the prevalence of HIV infection among prisoners was shown to vary depending on its prevalence in wider society, sampling method and current policy for dealing with drug users. It was shown to usually be higher in the prison society such that the rate of HIV/AIDS prevalence among Iranian, American and French prisons were 8, 5.5, and 10 times higher than in the wider society, respectively.

In this study, general prevalence of HIV/AIDS varied between 0% and 24.40% among prisoners. Similarly, HIV/AIDS prevalence in different countries also varies. For example, its rate was reported as 0-2% in Australia, 0-26% in England, 0-1% in Ireland, 1-10% in Canada, and 4% in six other European countries including France, Germany, Italy, Netherland, Scotland and Sweden and up to 35% in Argentina. A number of factors are shown to influence incidence and prevalence of HIV/AIDS among prisoners; the most important of these are discussed below.
Prevalence of HIV/AIDS among Iranian Prisoners

Table 1. HIV prevalence among prisoners of intravenous drug users

| Author (resource) | Place of study performance | Year of performance | Sample volume | Prevalence STI (%) | HIV prevalence among women (%) | HIV prevalence among men (%) | HIV prevalence (%) |
|-------------------|-----------------------------|---------------------|---------------|-------------------|-------------------------------|----------------------------|-------------------|
| Jahani et al.     | Tehran                      | 2006                | 499           | N/A               | N/A                           | N/A                        | 24.40             |
| Hosseini et al.   | Tehran                      | 2006                | 417           | 7.40              | N/A                           | N/A                        | 24.40             |
| Shahbazi et al.   | Iran                        | 1997                | 2022          | N/A               | N/A                           | N/A                        | 0.15              |
| Shahbazi et al.   | Iran                        | 1998                | 2367          | N/A               | N/A                           | N/A                        | 0.30              |
| Shahbazi et al.   | Iran                        | 1999                | 1670          | N/A               | N/A                           | N/A                        | 0.48              |
| Shahbazi et al.   | Iran                        | 2000                | 2553          | N/A               | N/A                           | N/A                        | 3.17              |
| Shahbazi et al.   | Iran                        | 2001                | 4556          | N/A               | N/A                           | N/A                        | 2.17              |
| Shahbazi et al.   | Iran                        | 2002                | 5881          | N/A               | N/A                           | N/A                        | 4.01              |
| Shahbazi et al.   | Iran                        | 2003                | 4515          | N/A               | N/A                           | N/A                        | 3.39              |
| Shahbazi et al.   | Iran                        | 2004                | 3824          | N/A               | N/A                           | N/A                        | 4.11              |
| Shahbazi et al.   | Iran                        | 2005                | 4920          | N/A               | N/A                           | N/A                        | 4.86              |
| Shahbazi et al.   | Iran                        | 2006                | 5226          | N/A               | N/A                           | N/A                        | 2.99              |
| Shahbazi et al.   | Iran                        | 2007                | 4571          | N/A               | N/A                           | N/A                        | 2.34              |
| Azarkar and Sharifzadeh | South Khorasan | 2008                | 358           | 16.80             | 0                             | 0                           | 0                 |
| Kazerouni Afsar et al. | Shiraz | 2007                | 363           | N/A               | N/A                           | N/A                        | 6.60              |
| Mir-Nasser et al. | Tehran                      | 2001                | 392           | N/A               | N/A                           | N/A                        | 17.00             |
| Rahbar et al.     | Mashhad                     | 2001                | 101           | 28.60             | N/A                           | 7.00                       | 7.00              |
| Farhoudi et al.   | Tehran                      | 2003                | 740           | N/A               | N/A                           | N/A                        | 23.20             |
| MENA report       | Iran                        | 2003                | N/A           | N/A               | N/A                           | N/A                        | 24.00             |
| MENA report       | Iran                        | 2009                | N/A           | N/A               | N/A                           | N/A                        | 24.40             |
| MENA report       | Hamedan                     | 2005                | 427           | N/A               | N/A                           | 0.90                       | 0.90              |
| Khodabakhshi et al. | Golestan   | 2002-2003           | 121           | N/A               | N/A                           | N/A                        | 5.80              |
| Khani and Vakili  | Zanjan                      | 2001                | 346           | N/A               | N/A                           | N/A                        | 1.20              |
| Ilami et al.      | Yasooj                      | 2009-2010           | N/A           | N/A               | N/A                           | N/A                        | 9.90              |
| Pourahmad et al.  | Iran                        | 2003                | 1431          | N/A               | N/A                           | N/A                        | 6.40              |
| Davoodian et al.  | Bandarabas                  | 2002                | 252           | N/A               | N/A                           | N/A                        | 15.10             |

STI: Sexually transmitted infection; MENA: Middle East and North Africa
Table 2. HIV prevalence among prisoners (others)

| Author (resource)          | Place of study performance | Year of performance | Sample volume | Prevalence STI (%) | HIV prevalence among women (%) | HIV prevalence among men (%) | HIV prevalence (%) |
|---------------------------|-----------------------------|---------------------|---------------|--------------------|--------------------------------|------------------------------|-------------------|
| Haghshenas et al.28       | Mazandaran                  | 1997-1998           | 650           | N/A                | 0                              | 0                            | 0                 |
| Management Center of Diseases29 | Khuzestan                    | 2007               | 804           | N/A                | N/A                           | 2.00                         | 2.00              |
| Control Center of Diseases30 | Kerman                      | 2008               | 400           | N/A                | N/A                           | N/A                          | 2.00              |
| Control Center of Diseases31 | Kermanshah                  | 2007               | 806           | N/A                | N/A                           | N/A                          | 5.20              |
| Khamisipoor and Tahmasebi32 | Bushire                      | 2007               | 126           | 2.38               | 0                             | 0                            | 0                 |
| Nokhodian et al.33        | Esfahan                      | 2009               | 163           | N/A                | 0                             | N/A                          | 0                 |
| Moosazadeh et al.34       | Mazandaran                   | 2008               | 2450          | N/A                | N/A                           | N/A                          | 0.30              |
| Haghdoost et al.35        | Iran                         | 1990-2000          | 392           | N/A                | N/A                           | N/A                          | 2.80              |
| Navadeh et al.36          | Iran                         | 2009               | 5530          | N/A                | 1.90                          | 2.10                         | 2.10              |
| MENA report (Qanad)32      | Iran                         | 2009               | N/A           | N/A                | N/A                           | N/A                          | N/A               |
| MENA report (Qanad)32      | Iran                         | 2009               | N/A           | N/A                | N/A                           | N/A                          | N/A               |
| MENA report (Qanad)32      | Iran                         | 2009               | N/A           | N/A                | N/A                           | N/A                          | N/A               |
| MENA report (Qanad)32      | Iran                         | 2009               | N/A           | N/A                | N/A                           | N/A                          | N/A               |
| Ghanbarzadeh and Nadjafi-Semnani37 | South Khorasan | 2006               | 199           | N/A                | N/A                           | N/A                          | 0                 |
| Tajbaksh and Yaghubi39     | Chaharmahal and Bakhtiar      | 2007               | 600           | 16.00              | 66.00                         | 66.00                         | 0.82              |

STI: Sexually transmitted infection; MENA: Middle East and North Africa
Prevalence of HIV/AIDS among Iranian Prisoners

Frequency of imprisonment
Prisons play a key role in expanding the incidence of HIV/AIDS in society, especially among intravenous drug users. Hence, effective and large is this role that many studies have shown a meaningful relation between the experience of being imprisoned in the past and associated drug use with disease infection. Being imprisoned is considered as a common event among intravenous drug users such that in low- and medium-income societies, more than 60% of people have experienced living in prisons.1,44 The rate of imprisonment in Middle East and North Africa region is very similar to other parts of the world. Its rate was estimated at 191 individuals per 100000 in Iran in 2007, 121 and 141 people per 100000, respectively, in Egypt and Lebanon.22 In this study, the rate of imprisonment in the past among prisoners was between 38.20% based on Ghanbarzadeh and Nadjafi-Semnani’s study37 and 81.30% according to Farhoudi et al.’s study.21

Intravenous drug using and addiction rate
In Iran, statistics show that about half of prisoners are addicted to drugs45 and one of the most important reasons for imprisonment of these people relates directly to this addiction. They also show that number of individuals infected by HIV/AIDS has reached 26,556 cases in Iran in 2013, while 68.40% of infection related to intravenous addiction.46 This highlights one of the important concerns about HIV/AIDS prevalence in prisons, particularly when many of prisoners were not drug users at first but later became addicted through the conditions dominant in the prisons, notably by injectable drugs where they were not initially intravenous users but became so by living in prisons.47

The lack of availability of drugs and ability to pay its high prices has contributed to prisoners becoming intravenous users as a way to reach highest satisfaction with minimum use as compared with other methods. This point highlights the important role of prisons in increasing disease prevalence and outbreak. HIV prevalence was higher in this group relative to other groups such that in many countries including China, Thailand and Malaysia, HIV has become an explosive epidemic.10,21 Experience of drug using has been reported between 30.7% and 54.3% among prisoners of Iran and 67.0% among those in Algeria. In this study, the experience of drug use in prison has varied; the maximum being 80.0% based on Pourahmad et al.’s study36 and the minimum being 16.5% according to Haghdoot et al.’s study.35

Drug using rate in Iranian prisons has not shown an upward trend over the years, with some exceptions, this decreasing rate is due to increased knowledge about the harmful effects of drug using, a relative improvement of prisons’ status in welfare and sport facilities, establishing centers for addiction treatment and using replacement methods as MMT. Intravenous addiction in prison has been reported between 27.60% and 53.60% among prisoners of Iran.22

In published studies, the intravenous addiction rate varied, including 3.2% in Nokhodian et al.’s study,33 6.1% in Kheirandish et al.’s,15 37.0% in Khani and Vakili’s,24 and 37.4% in Kazerooni Afsar et al.’s.18 Investigation of intravenous drug using in studies has shown a decreasing trend of the rate in recent years such that this amount has fallen from 37.0% in 2001 based on Khani and Vakili24 to 6.5% in 2006 based on Hosseini et al.16 This reduction can be attributed strategies such as harm reduction, greater coverage with methadone maintenance therapy, increased knowledge level in society and a better-informed media. Most studies related to Tehran in this study with high amounts not observed in other province. This highest prevalence noted in Tehran needs further research. In spite of a relatively tangible reduction observed in amount of drug using in recent years, Iran remains among the countries with a higher prevalence of intravenous drug using. For this reason, it seems necessary to implement preventive measures to reduce prisoners’ tendency to drug using and intravenous addiction.

Sharing non-sterile syringes in drug use
It has been noted in the literature that 56.0% of recent infections occurring in 2010 in Iran are due to insecure intravenous drug using.48 Intravenous drug using has been strongly related to HIV infection in 10 European cities.49,50 In current research, a high percentage of participants mentioned that disposable syringes (71.0%,31 68.1%,16 and 54.4%29) were available, but the rate of sharing on-sterile syringes was still high among prisoners. Incidence rates relate values of 16.8%,22 58.8%,26 48.5%,20 and 55.0%.36 Of course, these
values are similar to other countries’ statistics including Ireland (70.5%), Greece (49.8%), Belgium (47.0%), Italy (34.0%), France (32.0%), and Sweden (30.0%). This suggests that measures implemented in the form of harm reduction programs in the prisons have not shown considerable results without training and knowledge.

Sex

Intravenous drug using and risky sexual behaviors have been identified as the most significant factors increasing the HIV infection rate in Iran. In this research, unsafe sexual activity rate in Iranian countries was 17.0% and 5.0%, and sex between males in prison was 5.4% and 5.8%; in comparison, experience of illegal sexual intercourse out of prison showed different values of 18.4%, 27.8%, 9.5%, 6.1%, and 28.4%. Male-male sexual intercourse has been estimated as being 2.60% in Lebanon and 4% in Pakistan. Although intravenous addiction has shown a descending trend, epidemiological variation trends of AIDS transfer among drug addicts and youth has changed from same syringe use to risky sexual behaviors. Measures taken by Health Ministry, Prisons Organizations, and Welfare Organizations have increasingly controlled intravenous addiction, but in recent years, drug users especially among younger people have trended more toward psychotropic drugs and amphetamines. This increases HIV/AIDS transfer probability by risky sexual behaviors because of influences that these drugs have on individuals’ sexual activity. For this reason, preventive and controlling training programs are needed in this group.

Tattoos

Tattoos can be risk factors that increase incidence and prevalence of HIV/AIDS in prisons. In some studies, a high prevalence for disease from sharing tattooing devices has been mentioned. The transfer danger of HIV infection can be decreased by training and raising individuals’ knowledge to avoid tattooing altogether or by doing it in a safe way.

Strategies for harm reduction in prisons

MMT

Worldwide, there is a popular belief that the main method for controlling HIV/AIDS among intravenous drug addicts is by systematically and successfully implementing damage reduction plans. In Iran, as in other countries, measures are taken for reducing the prevalence and incidence of HIV/AIDS in both the wider society and among groups at greater risk such as prisoners. Damage reduction includes different strategies such as MMT and distributing disposable syringes. In addition to its advantages for preventing infections from intravenous injection, MMT has a key role in reducing the economic load related to drug abuse. Universally, MMT is considered as the principle preventive measure for reducing infections by drug injection in prisons and plays a significant role in preventing new cases of HIV. For example, in a study conducted in China in 2007, HIV infection has been respectively prevented by 3722 and 1960 cases during 10 years in high and low risk regions by performing MMT plan for 5 years. At present, damage reduction programs are in progress with acceptable coverage in Iranian prisons such that between 2002 and 2008, the number of prisoners received methadone has fallen from 100 to 25000 people. Iran now has one of biggest profiles of implementing this program among the world’s prisons by supporting about 38000 persons with MMT. Initial estimates were that this program would be able to save more than 100000 dollars for each case of HIV prevented and would reduce state costs. Although using this type of program may not completely interrupt drug abusing, it leads to improvement in drug addicts’ social function; as well reducing physical effects, guilt and crime, school drop-out, professional decline, psychological effects such as depression, and social and familial conflicts. Enforcement of individuals’ participation and continuous application of this method even after leaving the prison represent its positive and acceptable influences. Thus, continuing damage reduction programs such as MMT must be of even greater interest to authorities and those responsible for prevention and control of HIV/AIDS.

Using condoms

Correct and proper application of a condom has significantly reduced exposure to venereal diseases; the rate reduction has reached 80% or more in some studies. Using a condom is
therefore considered as one of the main parts of HIV prevention. One study showed 12.10% of prisoners experienced sexual intercourse and of this population only 15.4% used condoms. In a study involving 5530 prisoners in 27 Iranian prisons in 2001, 24.7% of prisoners had not used a condom in their last sexual intercourse. Incidence of HIV among groups at risk such as prisoners can be prevented by appropriate distribution of condoms within prisons and training about disease transmission.

**Using disposable syringes**

As mentioned previously, more than half of infections by HIV/AIDS in Iran are due to risky intravenous drug addiction. Although the prisoners’ access to sterile and disposable syringes was high in various studies, there remains a large gap from the desired coverage and reducing incidence cases related to this method of addiction. In 2008, there were about 250000 intravenous drug addicts in Iran, of which 5-20% had been infected by AIDS virus. Of interest is that only 7.5% intravenous drug addicts have access to centers for syringe distribution and healthy injective devices. With the daily expansion of intravenous drug addiction, it seems that increasing damage reduction by providing syringe and injection sterile devices, as well as training programs that inform society and at-risk groups can be effective in controlling HIV in Iran.

**Training**

Prevention is proposed as the most important way to deal with the HIV/AIDS epidemic worldwide. Training and developing the knowledge level within society is also one of its key preventive principles. One important obstacle for improving and developing AIDS prevention is a general lack of knowledge about variant aspects of the disease. In a study that assessed knowledge and attitude in Iranian society toward HIV/AIDS, knowledge level has met acceptable minimum but need of purposive and practicable planning is felt to promote society’s knowledge and attitude level comparing global criteria. Only 20.50% of Iranian prisoners Hassan acceptable knowledge level and possesses information about HIV/AIDS. It seems that AIDS knowledge and attitudes still need development and promotion, as well as through the use of correct training methods and making training processes more widely available.

In spite of the existing capacity and potential in Iran to offer control and prevention services for AIDS, we are still observing a continued incidence of this disease. Groups in danger, such as prisoners, have a high chance of infection and because they have a role in the prevalence and transfer of this disease from groups with high risk to the wider population; they must be further supervised and controlled and encouraged to take advantage increased education, services and facilities regarding reducing infection and transfer to others.

**Limitations**

Limitations in this research measuring HIV prevalence among prisoners relate to the nonspecificity of the subjects; different methods, objectives, and tools used; diverse tools and methods of gathering information; limited availability; limited accuracy of analysis of the tools used. We must note, of course, that it is necessary to undertake regular and periodical studies in varied settings to evaluate variation trends, including variations in disease prevalence.

**Conclusion**

In this study, HIV prevalence among prisoners and different subgroups in different studies varied widely and in many cases, this value was higher in Iran than other countries. The highest prevalence of HIV was due among intravenous users. If proper preventive and control plans are not implemented in a timely and suitable manner in at-risk groups such as prisoners, there is a risk that HIV/AIDS infection will increase in the wider society. It is critical that we prevent and manage this disease in society by having better understanding about the current status of the diseases, facing risks and threats, as well as implementing harm control and reduction programs for at-risk groups.

**Conflict of Interests**

The Authors have no conflict of interest.

**Acknowledgements**

We are grateful to all those who offered suggestions as to relevant studies, and to all authors who responded to the requests for clarification or additional information.
Prevalence of HIV/AIDS among Iranian Prisoners

References

1. Dolan K, Kite B, Black E, Aceijas C, Stimson GV. HIV in prison in low-income and middle-income countries. Lancet Infect Dis 2007; 7(1): 32-41.
2. Shahbazi M, Farnia M, Moradi G, Ebrahimi B. The trend of HIV/AIDS prevalence among IDU’s in Iranian prisoners (1376-1386). Retrovirology 2010; 7(Suppl 1): P101.
3. Gaughwin M, Douglas RM, Wodak AD. Behind bars-risk behaviours for HIV transmission in prisons, a review [Online]. [cited 1991]; Available from: URL: http://www.aic.gov.au/media_library/publications/proceedings/04/gaughwin.pdf
4. Epperson MW, Khan MR, El-Bassel N, Wu E, Gilbert L. A longitudinal study of incarceration and HIV risk among methadone maintained men and their primary female partners. AIDS Behav 2011; 15(2): 347-55.
5. Hellard ME, Aitken CK. HIV in prison: What are the risks and what can be done? Sex Health 2004; 1(2): 107-13.
6. Wohl DA, Rosen D, Kaplan AH. HIV and incarceration: dual epidemics. AIDS Read 2006; 16(5): 247-60.
7. Martin V, Cayla JA, Moris ML, Alonso LE, Perez R. Predictive factors of HIV-infection in injecting drug users upon incarceration. Eur J Epidemiol 1998; 14(4): 327-31.
8. Harding TW. AIDS in prison. Lancet 1987; 2(8570): 1260-3.
9. Tajbaksh E, Yaghubi R. Serologic evaluation of HIV contamination in Shahrekord prisoners through ELISA and Western blot. Sci J Iran Blood Transfus Organ 2008; 4(5): 365-9. [In Persian].
10. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: A review. Clin Infect Dis 2002; 35(3): 305-12.
11. Farnia M, Ebrahimi B, Shams A, Zamani S. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran. Int J Drug Policy 2010; 21(5): 422-4.
12. Zamani S, Farnia M, Torknejad A, Alaei BA, Gholizadeh M, Kasraee F, et al. Patterns of drug use and HIV-related risk behaviors among incarcerated people in a prison in Iran. J Urban Health 2010; 87(4): 603-16.
13. Seal DW. HIV-related issues and concerns for imprisoned persons throughout the world. Curr Opin Psychiatry 2005; 18(5): 530-5.
14. Jahani MR, Kheirandish P, Hosseini M, Shirzad H, Seyedalinaghi SA, Karami N, et al. HIV seroconversion among injection drug users in detention, Tehran, Iran. AIDS 2009; 23(4): 538-40.
15. Kheirandish P, Seyedalinaghi SA, Hosseini M, Jahani MR, Shirzad H, Foroughi M, et al. Prevalence and correlates of HIV infection among male injection drug users in detention in Tehran, Iran. J Acquir Immune Defic Syndr 2010; 53(2): 273-5.
16. Hosseini M, SeyedAliNaghi S, Kheirandish P, Esmaeli JG, Shirzad H, Karami N, et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med 2010; 13(4): 318-23.
17. Azarkoohi Afsar P, Amini Lari M, Joolaei H, Parsa N. Knowledge and attitude of male intravenous drug users on hiv/aids associated high risk behaviors in Shiraz Pir-Banon Jail, Fars Province, Southern Iran. Iran Red Crescent Med J 2010; 12(3): 334-6. [In Persian].
18. Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon 2011; 11(1): 19-22.
19. Rahbar AR, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy 2004; 15(2): 151-5.
20. Farhoudi B, Montevalian A, Motamed M, Khameneh MM, Mohraz M, Rassolnejad M, et al. Human immunodeficiency virus and HIV-associated tuberculosis infection and their risk factors in injecting drug users in prison in Iran. Tehran, Iran: Ministry of Health and Medical Education; 2003. [In Persian].
21. Akbari FA, Semini I. Characterizing the HIV/AIDS Epidemic in the Middle East and North Africa: Time for Strategic Action. Washington, DC: World Bank Publications; 2010.
22. Khodabakhshi B, Abbasi A, Fadaye F, Rabiee M. Prevalence and Risk Factors of HIV, Hepatitis B Virus and Hepatitis C Virus Infections in Drug Addicts among Gorgan Prisoners. J Med Sci 2007; 7(252): 254.
23. Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis b virus and hepatitis c virus infections in drug addicts among Zanjan prisoners. Archives of Iranian Medicine 2003; 6(1): 1-4.
Prevalence of HIV/AIDS among Iranian Prisoners

25. Ilami O, Sarkari B, Khosravani A, Tori MA, Hosseini Z. HIV seroprevalence among high-risk groups in Kohgiluyeh and Boyerahmad Province, Southwest of Iran: a behavioral surveillance survey. AIDS Behav 2012; 16(1): 86-90.

26. Pourahmadi M, Javady A, Karimi I, Ataei B, Kassaeian N. Seroprevalence of and risk factors associated with hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners in Iran. Infect Dis Clin Pract 2007; 15(6): 368-72.

27. Davoodian P, Dadvand H, Mamoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran. 2002. Braz J Infect Dis 2009; 13(5): 356-8.

28. Haghshenas MR, Mirmobini SM, Babamahmodi F. Prevalence of TB and HIV in prison in the city of Sari 1997-1998. J Mazandaran Univ Med Sci 2000; 9(26): 6-7. [In Persian].

29. Center for Disease Control, Ministry of Health. Boi behavioural survey on HIV/AIDS among Khoozestan prisoners; 2008. [Unpublished]. [In Persian].

30. Center for Disease Control, Ministry of Health. Study of the prevalence of Neisseria Gonorrhoeae, Clamidia Trachomatis, Syphilis and HIV in Kerman prisoners; 2008. [Unpublished]. [In Persian].

31. Center for Disease Control, Ministry of Health. Boi behavioural survey on HIV/AIDS among Kermanshah prisoners; 2008. [Unpublished]. [In Persian].

32. Khamisipoor G, Tahmasebi R. Viral infection of HBV, HCV, HIV and syphilis among high-risk groups, Bushehr. Iran South Med J 1999; 3(1): 53-9.

33. Nokhodian Z, Yazdani MR, Yaran M, Shoaei P, Mirian M, Ataei B, et al. Prevalence and Risk Factors of HIV, Syphilis, Hepatitis B and C Among Female Prisoners in Isfahan, Iran. Hepat Mon 2012; 12(7): 442-7.

34. Moosazadeh M, Amiresmailli M, Parsaei M, Ahmadi M, Jalali H. Prevalence of tuberculosis among the prisoners of Mazandaran. J Rafsanjan Univ Med Sci 2011; 10(4): 309-16. [In Persian].

35. Haghdoost AA, Mirzazadeh A, Shokoohi M, Sedaghat A, Gouya MM. HIV trend among Iranian prisoners in 1990s and 2000s; analysis of aggregated data from HIV sentinel sero-surveys. Harm Reduct J 2013; 10: 32.

36. Navadeh S, Mirzazadeh A, Gouya MM, Farnia M, Alasvand R, Haghdoost AA. HIV prevalence and related risk behaviours among prisoners in Iran: Results of the national biobehavioural survey, 2009. Sex Transm Infect 2013; 89(Suppl 3): iii33-iii36.

37. Ghanbarzadeh N, Nadjafi-Semnani M. A Study of HIV and other sexually transmitted infections among female prisoners in Birjand. J Birjand Univ Med Sci 2006; 13(3): 9-15. [In Persian].

38. McDonald AM, Ryan JW, Brown PR, Manners CJ, Falconer AD, Kinmear RC, et al. HIV prevalence at reception into Australian prisons, 1991-1997. Med J Aust 1999; 171(1): 18-21.

39. Edwards A, Curtis S, Sherrard J. Survey of risk behaviour and HIV prevalence in an English prison. Int J STD AIDS 1999; 10(7): 464-6.

40. Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley F, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: A national cross sectional survey. BMJ 2001; 323(7323): 1209-13.

41. Gaiter J, Jürgens R, Mayer K, Hollibaugh A. Harm reduction inside and out: controlling HIV in and out of correctional institutions. AIDS Read 2000; 10(1): 45.

42. Rotily M, Weilandt C, Bird SM, Kall K, Van Haastrecht HJ, Iandolo E, et al. Surveillance of HIV infection and related risk behaviour in European prisons. A multicentre pilot study. Eur J Public Health 2001; 11(3): 243-50.

43. Sosa-Estani S, Rossi D, Weissenbacher M. Epidemiology of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in injection drug users in Argentina: High seroprevalence of HIV infection. Clin Infect Dis 2003; 37(Suppl 5): S338-S342.

44. March JC, Oviedo-Joekes E, Romero M. Factors associated with reported hepatitis C and HIV among injecting drug users in ten European cities. Enferm Infecc Microbiol Clin 2007; 25(2): 91-7.

45. Iran Drug Control Headquarters. Iran Drug Control Headquarters [Online]. [cited 2010]; Available from: URL: http://dchq.ir/html/index.php?Module=htmlpages&func=display&PID=37

46. Centre for Communicable Diseases Management. HIV infection and AIDS statistics in Iran. Tehran, Iran: Ministry of Health and Medical Education; 2013.

47. Day C, Nassirimanesh B, Shakeshaft A, Dolan K. Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J 2006; 3: 2.

48. Nasirian M, Doroudi F, Gooya MM, Sedaghat A, Haghdoost AA. Modeling of human immunodeficiency virus modes of transmission in Iran. J Res Health Sci 2012; 12(2): 81-7.

49. Wodak A, Cooney A. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva, Switzerland: World Health Organization; 2004.

50. Farnia M, Shahbazi M, Moradi G, Alizadeh S, Ebrahi B, Kandi Kalle M. Evaluation of Harm

Addict Health, Summer 2016; Vol 8, No 3

http://ahj.kmu.ac.ir, 5 July
reduction Programs in prisons from the attitude and viewpoint of Iranian prison staff. J Sch Public Health Inst Public Health Res 2013; 11(1): 29-44. [In Persian].

51. Keshtkaran A, Mirahmadi-zadeh A, Heidari A, Javanbakht M. Cost-effectiveness of Methadone Maintenance Treatment in Prevention of HIV Among Drug Users in Shiraz, South of Iran. Iran Red Crescent Med J 2014; 16(1): e7801. [In Persian].

52. World Health Organization. Condoms for HIV prevention [Online]. [cited 2009]; Available from: URL: http://www.who.int/hiv/topics/condoms/en/

53. Sieck CJ, Dembe AE. Results of a pilot study of pre-release STD testing and inmates' risk behaviors in an Ohio prison. J Urban Health 2011; 88(4): 690-9.

54. Mansorian M, Solhi M, Dehdari T, Taghdisi MH, Zamani Alviecheh F, Qorbani M, et al. The cause of utilization of shared needle among injecting drug users of Ahwaz city: A qualitative study. Razi J Med Sci 2012; 19(101): 31-9. [In Persian].

55. Auerbach JD, Coates TJ. HIV prevention research: Accomplishments and challenges for the third decade of AIDS. Am J Public Health 2000; 90(7): 1029-32.

56. Haghdoost A, Pourkhandani A, Motaghipisheh S, Farhoudi B, Fahimifar N, Sadeghirad B. Knowledge and Attitude concerning HIV/AIDS among Iranian Population: A Systematic Review and Meta-Analysis. Iranian Journal of Epidemiology 2011; 6(4): 8-20. [In Persian].
چکیده
مدله‌ی در سراسر دنیا، زندانیان بیشتر از گروه‌های برخوردار دیگر در معرض ابتلا به عفونت HIV قرار دارند. ابداع و زندان عواملی هستند که سلامت جامعه را تهدید می‌کند. رفتارهای برخوردار مؤثر در انتقال ایدز در بین زندانیان HIV بیشتر شایع است. این مطالعه با هدف جمع‌ینه‌ی اطلاعات و گزارش‌های منتشر شده در زمینه شیوع HIV در زندان‌های کشور انجام گرفت.

روش‌ها: پس از جستجوی مستندات در بایگانه‌های داخلی و خارجی، در مجموع 25 مطالعه مورد بررسی قرار گرفت و با مراجعه به خلاصه مقالات و منابع کامل آنها، اطلاعات مورد نیاز استخراج گردید.

بیانیه‌ها: مطالعات وارد شده از نظر متدولوژی (شیوه نمونه‌گیری و ابر گروه ارور اطلاعات) تفاوت‌های زیادی با یکدیگر داشتند. در مجموع، 25 مطالعه با موضوع حجم نمونه 3942 نفر مورد بررسی قرار گرفت که شیوع HIV در این مطالعات از صفر تا 1 درصد متغیر بود.

نتیجه‌گیری: در این پژوهش، شیوع HIV در زندان‌های داخلی و خارجی افزایش یافته و این مقدار از بسیاری از کشورهای دیگر بالاتر بود. به‌طور کلی، این پژوهش نشان می‌دهد که به‌طور کلی، شیوع HIV در این بخش‌ها از نظر متبنا باعث افزایش بسیاری از بسیاری از کشورهای دیگر بالاتر می‌شود.

واژگان کلیدی: AIDS، HIV، زندان، ایران، شیوع، وقوع

ارجاع: آکبری، اکبری مریم، چمران زینب، گزارش‌های منتشر شده در زمینه شیوع HIV در زندان‌های کشور در سال‌های 1980 تا 1995. مجله اخلاق و سلامت، شیراز، ایران

تأثیر دیپش: 94/11/29

Email: lankaran@sums.ac.ir

Prevalence of HIV/AIDS among Iranian Prisoners

Akbari et al.